Discovering New Treatment Targets on Cancer Cells
NOVEL BREAST CANCER SURFACE ANTIGEN SLC39A7 (ZIP7) PRESENTED AT AACR 2024
AACR PRESENTATION
PREVIOUS ASCO PRESENTATION
Cancer Antibodies Inc is a 501(c)(3) non-profit organization. Donations are tax-deductible as allowed by U.S. law.
DISCOVERY
We have achieved a breakthrough in the struggle to differentiate between normal and cancer cells.
Using a novel method, we have developed a platform that identifies unique targets (neoantigens) on the surface of cancer cells and not normal cells. When those unique sites are targeted, cancer cells can be preferentially killed while leaving nearby normal cells unharmed. The method can be applied to any type of cancer.
We are looking for partners & collaborators to help carry this research to the clinic and start saving lives.
The results of a study using our platform were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
NEW ANTIGENS
Following the presentation at ASCO, successful independent collaborations with partners resulted in the identification of multiple new cell surface proteins (antigens) on triple negative breast cancer that have not been targeted before.
The importance of this cannot be overstated. Existing treatments virtually always stop working because whatever is being targeted on the cancer cells mutates and the therapy becomes no longer effective.
Existing research methods focused on target discovery often takes a decade or more to find a single antigen. Techniques such as DNA sequencing often identify mutations or other changes inside cancer cells, which are not able to be targeted.
In contrast, our platform finds new antigens (targets) and generates antibodies against multiple new (previously unknown) cancer-specific antigens in a matter of months.
These unique antigenic targets reside on the cell surface and are able to be used for the precision killing of cancer.
PUBLICATION & PRESENTATION
American Association for Cancer Research (AACR) 2024
The novel breast cancer surface antigen SLC39A7 (ZIP7) was discovered by CAI and presented at the American Association for Cancer Research (AACR) Annual Meeting on April 9, 2024.
American Society of Clinical Oncology (ASCO)
An abstract embodying our novel method and research results was published by the American Society of Clinical Oncology (ASCO) on May 26, 2022. The results of our study were presented at the ASCO Annual Meeting in June 2022 with over 40,000 attendees.
ASCO is the largest and one of the most prestigious oncology organizations in the world, with its annual conference attended by cancer researchers and clinical oncologists from around the world.
Highlights of the abstract include:
- Antibodies generated against a specific type of cancer can kill those cancer cells without harming normal cells from the same tissue type and the same person.
- These antibodies against one person’s cancer can kill the same cancer type from a different person.
- These antibodies surprisingly can also kill cancer cells of a different type than the kind they were derived against.
- Antibodies generated against one person’s cancer do not harm normal cells from a different person.
- The platform can generate antibodies against a variety of cancers.
Publication in the Journal of Clinical Oncology
An abstract embodying our novel method and research results was published by the American Society of Clinical Oncology (ASCO) on May 26, 2022.
ASCO 2022 Annual Meeting Poster Presentation
The results of our study were presented at the ASCO Annual Meeting in June 2022 with over 40,000 attendees.
VIDEO: ASCO 2022 Poster Presentation
CHALLENGE & SOLUTION
There are two primary reasons cancer has not been cured yet:
1. Current treatments also kill normal cells which results in pain, suffering and often death by the patient.
2. The cancer cells mutate and the treatment becomes no longer effective.
This new method offers a solution to both of these challenges.
When these unique surface antigens are targeted, normal cells are not killed. And, if cancer cells mutate, the technique can be utilized to find new targets that exist on the newly mutated cancer cells.
Cancer is clearly the deadliest disease in the developed world. In the U.S., one in three women and one in two men will develop cancer in their lifetime. Not one age group or demographic escapes the devastating diagnosis of cancer. It’s the second leading cause of death in the U.S. and around the world with an estimated 9.5 million people dying of the disease each year.
These shocking statistics clearly show that existing therapies are not effective enough and new methods are desperately needed.
All cells, including cancer cells, have areas that can bind antibodies, called antigens. If unique cancer specific surface antigens are found, they can be targeted to kill cancer cells and not normal cells. Cancer Antibodies’ method can identify multiple unique cancer-specific surface antigens that exist only on cancer cells. Therapeutic antibodies can be developed to target these unique sites. The method is applicable across different types of cancer.
PARTNERS
Just like the immune system needs millions of antibodies to take action in order to make a difference, together we can have a tremendous impact.
Here is how you can help make a difference.
Experts, Labs, Resources
Partner with expertise, labs and resources. Get involved now!
Share Our Mission
We want the world to be as excited about this as we are. Share on social media & more!